Likewise, ACKR3 expression is increased during experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis (MS), which is ameliorated by treatment with an ACKR3 antagonist6, whereas astrocytic Cx43 expression is decreased in MS and other inflammatory demyelinating brain disorders. This evidence concerns the gene ACKR3 and myeloid sarcoma.